Purpose To evaluate whether intraprocedural 3D quantification of Lipiodol deposition on cone-beam computed tomography (CBCT) can predict tumor response on followup contrast-enhanced magnetic resonance imaging (CE-MRI) in patients with hepatocellular carcinoma (HCC) treated with conventional transarterial chemoembolization (cTACE). Materials and Methods This IRB approved, retrospective analysis included 36 patients with 51 HCC target lesions, who underwent cTACE with CBCT. CE-MRI was acquired at baseline and 1 month after cTACE. Overall tumor volumes as well as intratumoral Lipiodol volumes on CBCT were measured and compared with the overall and necrotic (non-enhancing) tumor volumes on CE-MRI using the paired student's t test. Tumor response on CE-MRI was assessed using modified response evaluation criteria in solid tumors (mRECIST). A linear regression model was used to correlate tumor volumes, Lipiodol volumes, and the percentage of Lipiodol deposition on CBCT with the corresponding parameters on CE-MRI. Nonparametric spearman rank-order correlation and trend test were used to correlate the percentage of Lipiodol deposition in the tumor with tumor response. Result A strong correlation between overall tumor volumes on CBCT and CE-MRI was observed (R 2 = 0.986). In addition, a strong correlation was obtained between the volume of Lipiodol deposition on CBCT and tumor 
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Introduction
Two landmarks studies have demonstrated survival benefits for patients who were treated with conventional transarterial chemoembolization (cTACE) compared to symptomatic treatment [1, 2] . Although overall survival continues to be the ultimate end point in cTACE clinical trials, imaging biomarkers of tumors response are frequently used as surrogates for TACE efficacy [3] [4] [5] . In this context, identifying non-responders as early as possible is of high clinical relevance for the decision on whether or not to retreat the patient [6, 7] . Some studies have identified intratumoral Lipiodol deposition as a strong biomarker of tumor necrosis and have confirmed it to be a predictor of tumor response and potentially survival outcomes after cTACE [3, 5, [8] [9] [10] [11] [12] . Many of these reports relied on postprocedural multi-detector CT (MDCT) in order to assess the Lipiodol distribution after cTACE, thus making the feedback available only upon completion of the procedure. In addition, most intraprocedural evaluation relied on non-quantitative and two-dimensional (2D) fluoroscopic assessment or manual measurements of the Lipiodol deposition. In this context, the emerging role of intraprocedural cone-beam computed tomography (CBCT) has not yet been fully explored [5, 11] . The advent and growing availability of immediate, intraprocedural CBCT offers immediate cross-sectional analysis of the Lipiodol deposition [13] . In addition, the development of new 3D quantitative assessment tools provides the basis for objectifying the visual impression by volumetrically quantifying the distribution and deposition of Lipiodol immediately after injection [4, 5, 14] . Previous studies validated the ability of 3D image analysis to accurately quantify the deposition of Lipiodol on CBCT [15, 16] .
The purpose of our study was to explore the use of intraprocedural CBCT for immediate 3D quantitative evaluation of Lipiodol deposition during cTACE as a predictor of tumor response on follow-up contrast-enhanced MRI (CE-MRI).
Materials and Methods

Patient Selection
This was a retrospective, single institution study, compliant with Health Insurance Portability and Accountability Act and approved by the institutional review board. Informed consent was obtained before cTACE in all patients. Diagnosis of HCC was confirmed by liver biopsy or by typical imaging features on dynamic CE-CT or CE-MRI (hypervascularity in the arterial phase and washout in the venous phase) and an alpha-fetoprotein level of 200 ng/mL or higher. Patients with unresectable HCC were referred to cTACE after discussion at the multidisciplinary liver tumor conference. Eligibility criteria for cTACE were as follows: focal or multifocal unresectable HCC; Child-Pugh classification A or B; Eastern Cooperative Oncology Group performance status 0 or 1, and no contraindication to contrast medium. The patients with tumor burden greater than 70 %, the presence of extensive extrahepatic disease, or complete tumor occlusion of the portal vein were excluded. The inclusion of target lesion into image analysis was based on the following eligibility criteria: (1) dynamic CE-MRI acquired within 1 month before and after cTACE; (2) intraprocedural CBCT acquired immediately after cTACE; (3) therapy-naive target lesion visualized without artifacts on both modalities; and (4) well-defined tumor borders. Patients and tumors that did not meet the aforementioned criteria were excluded from our study. Between June 2012 and February 2014, the liver tumor board discussed the care of 628 patients who had HCC. Of the 628 patients, 122 patients were treated with cTACE. Of those, 61 patients underwent CE-MRI within 1 month before and after the treatment, and intraprocedural CBCT immediately after TACE. 25 patients were excluded due to atypical lesion morphology, portal vein invasion, and breathing artifact on CE-MRI. Thus, the final analysis included a total of 36 patients with a total of 51 HCC target lesions.
Conventional TACE Protocol
cTACE was performed according to our standard institutional protocol, and all procedures were performed by an interventional radiologist (JFG) with 18 years of experience in hepatic interventions. With use of the Seldinger's technique, a 5-F vascular sheath was placed in the right common femoral artery over a 0.035-inch guide wire (Bentson, Cook, Bloomington, IN). Under fluoroscopic guidance, a 5-F glide Simmons-1 catheter (Cordis, Miami, FL) was advanced and formed into the aortic arch and then used to select the celiac axis. A 3-F Renegade High-Flo catheter was coaxially advanced through the glide catheter over a 0.014-inch Transcend wire (Boston Scientific, Natick, MA), and manipulated to achieve lobar or segmental catheterization. An emulsion containing 50 mg doxorubicin (Adriamycin; Pharmacia &Upjohn, Peapack, NJ), and 10 mg mitomycin C in a 1:1 mixture with lipiodol (Lipiodol; Guerbet, Paris, France) was infused and followed by the infusion of gelatin-coated trisacryl microspheres (Embosphere Microspheres; Biosphere Medical, Rockland, MA) until arterial inflow was substantially reduced as seen on fluoroscopy.
Intraprocedural C-Arm Cone-Beam CT All patients underwent CBCT immediately after TACE. Briefly, CBCT was performed using a commercially available angiographic system (Allura Xper FD20, Philips Healthcare, Best, The Netherlands) with the XperCT option, enabling CBCT acquisition and volumetric image reconstruction. Within 5 s, 312 projection images (60 frames per second) were acquired with the motorized C-arm covering a 240 o clockwise arc under a fixed 120 kVp setting. The two-dimensional projection images were reconstructed using Feldkamp back projection into 3D volumetric images for a 250 9 250 9 194 mm 3 field of view (matrix size 384 9 384 9 296) with a voxel size of 0.6 mm 3 . The patients were instructed to be at end expiration apnea during the CBCT scanning.
CE-MRI Technique
All patients underwent baseline and post-TACE CE-MRI using a 1.5-T MR unit (CV/I, GE Medical Systems, Milwaukee, WI) and a phased array torso coil within 4 weeks before cTACE. The imaging protocol included: (1) axial T2-weighted fast spin-echo images [repetition time (TR)/ echo time (TE), 5000/100 ms; matrix size, 256 9 256; slice thickness, 8 mm; interslice gap, 2 mm; receiver bandwidth, 32 kHz]; (2) axial single-shot breath-hold gradient-echo diffusion-weighted echo-planar images (TR/TE, 5000-6500/110 ms; matrix size, 128 9 128; slice thickness, 8 mm; inter slice gap, 2 mm; b value, 500 s/mm 2 ; receiver bandwidth, 64 kHz); and (3) axial breath-hold unenhanced and contrast-enhanced (0.1 mmol/kg intravenously of gadodiamide, Omniscan, General Electric, Princeton, NJ) T1-weighted three-dimensional fat-suppressed spoiled gradient-echo images (TR/TE, 5.1/ 1.2 m sec; field of view,320-400 mm 2 ; matrix size, 192 9 160; slice thickness, 4-6 mm; receiver bandwidth, 64-kHz; flip angle, 15) in the arterial and portal venous phases (20 and 70 s after intravenous contrast administration, respectively). The arterial of the CE-MRI was used for the study.
Quantitative Measurement of Lipiodol Deposition in Tumor on CBCT
The volumetric measurements of the overall tumor and Lipiodol deposition on CBCT were performed by an experienced interventional radiologist who did not perform the TACE procedure (ZW, 10 years of experience). Overall tumor volumes as well as the Lipiodol volumes (in cm 3 ) were measured using a semi-automated quantification software, which has been previously demonstrated as accurate and reproducible [15, [17] [18] [19] . Briefly, the quantification included three steps. First, the intraprocedural CBCT images were selected; second, a segmentation of the overall tumor volume including Lipiodol deposition was performed (Figs. 1, 2A, C) [17, 18] . Third, a region of interest based, semi-automatic quantification of the Lipiodol volume as well as percentage in relation to the overall tumors volume was performed (Figs. 1, 2E ) [15, 19] .
Quantitative Measurement of Tumor Necrosis on CE-MRI
Quantitative measurement of the overall as well as the nonenhancing necrotic tumor volume (as a surrogate for tumor necrosis) was performed using an analogous technique. Tumor enhancement was determined using the 3D semiautomated method as described in the previous section [15, 19] and is briefly described as follows: first, the specific CE-MRI scan was selected; second, a segmentation of the overall tumor volume was performed on the arterial phase CE-MRI (Figs. 1, 2B, D) . Third, average enhancement values were obtained from a region of interest formed by a 10 9 10 9 10 mm cube placed within non-enhancing, extra-tumoral liver parenchyma. Fourth, enhancing/viable tumor tissue was defined as areas within the tumor where the enhancement exceeded that of the extra-tumoral parenchyma. The enhancement was then expressed in cm 3 as well as a percentage of the total tumor volume (Figs. 1,  2F ). The reciprocal values were used to quantify tumor necrosis [20] . A color map was overlaid on the arterial phase CE-MRI in order to demonstrate the regional tumor enhancement heterogeneity. The red color represented maximum enhancement (viable tumor), and blue represented minimum enhancement (nonviable tumor).
Tumor Response Assessment of Target Lesions after cTACE
Tumor response of each target lesion was assessed by the same experienced radiologist according to the modified response evaluation criteria in solid tumors (mRECIST) [21] . Target tumor response was defined with the following four categories: complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD). CR: Disappearance of any intratumor arterial enhancement in target lesion. PR: at least a 30 % decrease in the uni-dimensional diameter of viable (enhancement in the arterial phase) target lesion, taking as reference the baseline enhancing diameter of target lesion. PD: an increase of at least 20 % in the diameter of viable (enhancing) target lesion, taking as reference the baseline enhancing diameter of target lesion. SD: changes that did not qualify for either PR or PD.
Statistics
Data analysis was performed using SPSS 15.0 (SPSS, Chicago, IL). The tumor volumes as well as the Lipiodol deposition volume and non-enhancing necrotic volume between CBCT and CE-MRI were compared using the two-tailed Student's t-test for paired data. Linear regression was used to correlate both volumes (cm 3 ) and percentage of Lipiodol deposition in the tumor and non-enhancement between CBCT and CE-MRI. Nonparametric Spearman rank-order correlation and nonparametric trend test were used to correlate percentage of Lipiodol deposition in the tumor and short-term response assessed using mRECIST. A P value \0.05 was considered statistically significant.
Results
Between June 2012 and February 2014, 36 patients were included in our study. There were twenty-nine men and seven women with a mean patient age of 57.6 ± 8.1 years (range, 44-89 years). A total of 51 target lesions (mean tumors per patient, 1.4; range, 1-2; mean tumor diameter 2.25 ± 1.02 cm) were included into the analysis (Table 1) .
Volumes of Tumor, Lipiodol Deposition, and Non-enhancement on CBCT and CE-MRI
The mean tumor volumes were 12.66 ± 12.76 cm 3 (range, 0.79-50.68 cm 3 ) on CBCT and 12.14 ± 13.18 cm 3 (range, Fig. 1 3D volumetric ), respectively, with no statistically significant difference between both modalities (P = 0.974).
Correlation of Tumor Volumes, Lipiodol Deposition on CBCT, and Non-enhancement on CE-MRI
A strong correlation between tumor volumes was observed on CBCT and CE-MRI (Fig. 3A) (coefficient of determination: R 2 = 0.986). A strong correlation between Lipiodol deposition volumes on CBCT and non-enhancing volumes on CE-MRI was observed (R 2 = 0.960) (Fig. 3B) . A strong correlation between % of Lipiodol deposition on CBCT and % of non-enhancement in tumor was also observed on CE-MRI (R 2 = 0.979, respectively) (Fig. 3C) .
Tumor Response at Follow-up MRI: Assessment with mRECIST
A CR was achieved in 26 HCC tumors, a PR in 11 lesions, and a SD was noted in 14 lesions. The mean % of Lipiodol deposition in the tumor was 97.22 ± 2.84 % in CR, 83.83 ± 11.45 % in PR, and 24.00 ± 19.18 % in SD. The nonparametric trend of percentage of Lipiodol deposition associated with ordinal levels of short-term response was highly statistical significant (P \ 0.001). There was a strong correlation between the % of Lipiodol deposition and tumor response (Spearman rho = 0.84, P \ 0.001) (Fig. 3D ).
Discussion
Our study demonstrates a strong correlation between the degree of Lipiodol deposition and necrotic non-enhancing tumor tissue on CE-MRI at 1-month follow-up. Furthermore, our study showed that 3D quantitative assessment of Lipiodol deposition on intraprocedural CBCT allowed monitoring and predicting short-term response at 1-month follow-up CE-MRI after cTACE in patients with HCC.
Tumor response is a predictive factor of survival [22, 23] . Early determination of therapeutic response is helpful to guide patient treatment decisions for potential repeat TACE or additional treatments after chemoembolization. Tumor pathology is the gold standard to assess tumor response. However, it is not feasible in clinical practice and so imaging techniques such as contrast-enhanced MDCT and MRI are widely used to determine tumor response after TACE in order to make early clinical decisions. A strong correlation of imaging-based measurements of tumor response to TACE with tumor pathology provides critical foundation to link radiological findings with actual therapeutic effect. However, current tumor response methods, such as mRECIST and the European Association for the study of the Liver (EASL) guidelines, have limitations in practice [24] . One of which is that they need upwards of 2 months after TACE to assess tumor response on follow-up imaging and so they can not provide immediate feedback [25] . Recently, functional imaging techniques such as CT perfusion, diffusion-weighted MRI, or PET-CT have been shown to exhibit changes hours to days after TACE to indicate treatment response, but the results of these approaches are variable and without standardized protocols [26, 27] .
The advent of new 3D methods of tumor assessment addresses the discordance between tumor diameter and non-spherical volume of the viable tumor tissue [28] . Based on workflow efficient and reproducible tumor segmentation software, these volumetric techniques include enhancement-based and diffusion-weighted MRI and are predictive of patient survival which address important concerns in regard to clinical practicability of 3D quantitative imaging [19, [29] [30] [31] . A previous study has demonstrated the strong diagnostic accuracy and repeatability of 3D quantitative CE-MRI techniques with regard to pathologically measured tumor necrosis in HCC tumors treated with TACE [20] . Based on these findings, the present study demonstrated a strong correlation between the degree of Lipiodol deposition (volume and %) as seen on intraprocedural CBCT and non-enhancement necrosis as seen on follow-up MR. Importantly, the results demonstrated a strong correlation between the degree of Lipiodol deposition and short-term tumor response expand a new application of CBCT in monitoring and quantification of tumor response to TACE intraprocedurally.
Compared with other conventional imaging techniques to determine intraprocedural Lipiodol deposition, such as fluoroscopy and MDCT, volumetric measurement on intraprocedural CBCT has several clinical advantages in practice. When compared with fluoroscopy, it is a 3D quantitative method, whereas fluoroscopy is a 2D qualitative method [32] . Compared with MDCT, it is workflow efficient and time saving to directly assess Lipiodol deposition after TACE without the need of transferring the patient to the MDCT room. Assessing Lipiodol deposition at time of TACE allows for intraprocedural feedback for modification of delivery endpoint [33] . CBCT has also lower radiation exposure than MDCT [34] . Although further technology development and intraprocedural workflow optimization are already on the horizon, CBCT with 3D segmentation software has already sufficient ability and repeatability to detect and volumetrically measure tumors as well as Lipiodol deposition [15] [16] [17] [18] 35] . Further, the new software used in our study has several unique advantages. First, it differentiates Lipiodol from tumor or liver parenchyma based on enhancement and calculates the volume of Lipiodol deposition. Second, it automatically measures the HU value of the Lipiodol deposition regions. Third, the degree of Lipiodol in tumor can be visualized clearly with different colors which can offer feedback for TACE [15] . Fourth, it requires only a single phase CBCT without the need of contrast media injection.
Our study had some limitations. First, the sample size was small. As the use of CBCT becomes more routine, we imagine the availability of imaging data to increase. Second, most of the tumors were small (mean diameter: 2.61 ± 1.10 cm). The results of our study should be validated in future studies that have more patients and larger lesions. The scope of our work was for therapy response assessment and in future work, prediction of overall survival using analysis of intraprocedural imaging would have even more clinical value. Third, only HCC lesions that had clear borders (not diffuse/infiltrative disease) were included in our study. In future work, using whole liver 3D segmentation could solve this limitation. As the visibility of lesions improves through developments in imaging, and as staging systems improve to better identify patients for this kind of therapy, we anticipate the findings of our study to be more generalizable.
Conclusion
Intraprocedural 3D quantification of Lipiodol deposition on CBCT can be used to predict tumor response on follow-up MRI.
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